Pharmaceuticals - Tunisia

Tunisia

In Tunisia, the revenue in the Pharmaceuticals market is estimated to reach US$266.40m in 2024.
Among the different markets, Oncology Drugs is anticipated to be the largest, with a projected market volume of US$49.12m in 2024.
Looking ahead, the revenue is expected to exhibit an annual growth rate (CAGR 2024-2028) of 5.55%, leading to a market volume of US$330.60m by 2028.
When compared globally, United States is forecasted to generate the highest revenue, amounting to US$636.90bn in 2024.
Recent regulatory reforms in Tunisia have created a favorable environment for pharmaceutical companies, attracting foreign investment and driving growth in the market.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Tunisia has been developing at a steady pace in recent years, with a growing demand for healthcare products and services in the country.

Customer preferences: Customers in Tunisia have been increasingly focused on preventive healthcare measures, leading to a rise in demand for pharmaceutical products such as vitamins and supplements. Additionally, there has been a growing demand for chronic disease treatments, particularly for diabetes and hypertension.

Trends in the market: One of the key trends in the Tunisian pharmaceuticals market has been the increasing adoption of generic drugs, which are more affordable than their branded counterparts. This has been driven by the government's efforts to reduce healthcare costs and increase access to essential medicines. Another trend is the growing investment in research and development by local pharmaceutical companies, which has led to the development of new drugs and therapies for various diseases.

Local special circumstances: Tunisia has a well-established healthcare system, with a mix of public and private healthcare providers. The government has been actively working to improve access to healthcare services, particularly in rural areas. Additionally, the country has a strong pharmaceutical manufacturing industry, which has been supported by government incentives and favorable investment policies.

Underlying macroeconomic factors: Tunisia has been experiencing steady economic growth in recent years, which has led to an increase in disposable income and consumer spending. This has been a key driver of growth in the pharmaceuticals market, as consumers are able to afford more healthcare products and services. Additionally, the government has been implementing policies to attract foreign investment and promote economic growth, which has led to increased investment in the healthcare sector. Overall, the Tunisian pharmaceuticals market is expected to continue growing in the coming years, driven by factors such as increasing demand for healthcare products and services, government initiatives to improve access to healthcare, and favorable economic conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.